Bioresponsive drug delivery systems for the treatment of inflammatory diseases

JOURNAL OF CONTROLLED RELEASE

卷:327

Article

Dou, Yin¹  Li, Chenwen¹  Li, Lanlan^1,2  Guo, Jiawei^1,3  Zhang, Jianxiang^1,4 

[1] Third Mil Med Univ, Coll Pharm, Dept Pharmaceut, Army Med Univ, Chongqing 400038, Peoples R China

[2] Third Mil Med Univ, Coll Basic Med, Dept Chem, Army Med Univ, Chongqing 400038, Peoples R China

[3] Third Mil Med Univ, Coll Pharm, Dept Pharmaceut Anal, Army Med Univ, Chongqing 400038, Peoples R China

[4] Third Mil Med Univ, Inst Burn Res, State Key Lab Trauma Burn & Combined Injury, Army Med Univ, Chongqing 400038, Peoples R China

关键词: Bioresponsive materials;    Reactive oxygen species;    Drug delivery;    Inflammatory diseases;    Nanoparticles;    Microparticles;    Hydrogels;   

DOI  :  10.1016/j.jconrel.2020.09.008

来源: Elsevier

【 摘 要 】

A Inflammation is intimately related to the pathogenesis of numerous acute and chronic diseases like cardiovascular disease, inflammatory bowel disease, rheumatoid arthritis, and neurodegenerative diseases. Therefore antiinflammatory therapy is a very promising strategy for the prevention and treatment of these inflammatory diseases. To overcome the shortcomings of existing anti-inflammatory agents and their traditional formulations, such as nonspecific tissue distribution and uncontrolled drug release, bioresponsive drug delivery systems have received much attention in recent years. In this review, we first provide a brief introduction of the pathogenesis of inflammation, with an emphasis on representative inflammatory cells and mediators in inflammatory microenvironments that serve as pathological fundamentals for rational design of bioresponsive carriers. Then we discuss different materials and delivery systems responsive to inflammation-associated biochemical signals, such as pH, reactive oxygen species, and specific enzymes. Also, applications of various bioresponsive drug delivery systems in the treatment of typical acute and chronic inflammatory diseases are described. Finally, crucial challenges in the future development and clinical translation of bioresponsive anti-inflammatory drug delivery systems are highlighted.

【 授权许可】

Free